Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | DHODH | Q02127 | 7/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180990 | 0.91 | PTGS2 (0.43) | PTGS2DHODHPDE3BPDE3AALOX5AP | |
| SCHEMBL17359248 | 0.84 | PDE3B (0.38) | PTGS2PDE3BPDE3AALOX5APFEN1 | |
| SCHEMBL17359247 | 0.84 | PTGS2 (0.43) | PTGS2PDE3BPDE3AAKR1C3PTGS1 | |
| SCHEMBL20687821 | 0.84 | PDE3B (0.43) | PTGS2DHODHPDE3BPDE3AESR1 | |
| SCHEMBL10014239 | 0.81 | PTGS2 (0.43) | PTGS2DHODHPDE3BPDE3AESR1 | |
| SCHEMBL17359262 | 0.78 | RPS6KA3 (0.46) | PTGS2PDE3BPDE3APTGS1 | |
| SCHEMBL15180996 | 0.78 | DHODH (0.40) | DHODHRAPGEF4 | |
| SCHEMBL17359263 | 0.78 | PTGS2 (0.42) | PTGS2PDE3BPDE3AESR1ESR2 | |
| SCHEMBL10014275 | 0.78 | RAPGEF4 (0.42) | DHODHRAPGEF4 | |
| SCHEMBL13986747 | 0.78 | RAPGEF4 (0.42) | DHODHRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527870-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX3, OCIAD1, PIEZO1 | PTGS2 4273/4885DHODH 4592/4885PDE3B 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.